← 홈

Antibody

55개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 55개
AntibodyHotRochevedotin, rituximab, cycloph…Approved

rituximab (rituximab)

Rheumatic Disease · FRα

#FR#Antibody#Approved#인기#항체+5
효능 ORR 100%임상시험 1091상태 DISCONTINUED
AntibodyRocheApproved

Mabthera (Mabthera)

Rheumatoid Arthritis · FRα

#FR#Antibody#Approved#인기#항체+5
효능 ORR 84.7%임상시험 69상태 ACTIVE
AntibodyBristol Myers SquibbPhase 2

Relatlimab (Relatlimab)

Various Advanced Cancer · FRα

#FR#Antibody#Phase2#인기#항체+5
효능 ORR 71.4%임상시험 62상태 RECRUITING
AntibodyPfizerApproved

Elranatamab (Elranatamab)

Multiple Myeloma · FRα

#FR#Antibody#Approved#인기#항체+5
효능 ORR 61%임상시험 54상태 RECRUITING
AntibodyPfizerPhase 2

PF-06863135 (Elranatamab, Elranatamab (PF-06863135))

Multiple Myeloma · FRα

#FR#Antibody#Phase2#인기#항체+5
효능 ORR 61%임상시험 51상태 ACTIVE
AntibodyEpizyme, Inc.vedotin in patients with re…Phase 3

Mosunetuzumab (Mosunetuzumab)

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · FRα

#FR#Antibody#Phase3#항체#면역항체+5
효능 ORR 87.5%임상시험 49상태 RECRUITING
AntibodyJanssenPhase 3

Talquetamab (Talquetamab)

Myeloma Multiple; Plasma Cell Leukemia · FRα

#FR#Antibody#Phase3#항체#면역항체+5
임상시험 40상태 DISCONTINUED
AntibodyRocheVedotin-Based Polatuzumab V…Phase 2

rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+5
효능 ORR 76%임상시험 32상태 RECRUITING
AntibodyRocheVedotin in Relapsed/Refract…Phase 2

Glofitamab/Obinutuzumab (Glofitamab/Obinutuzumab)

Richter Syndrome · FRα

#FR#Antibody#Phase2#항체#면역항체+5
효능 ORR 35.3%임상시험 31상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab cohort 1)

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 7%임상시험 30상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab cohort 2)

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 37.8%임상시험 30상태 RECRUITING
AntibodystaleMarcela V. Maus, M.D.,Ph.D.Phase 2

Emapalumab (Emapalumab)

Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 60%임상시험 29상태 RECRUITING
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Daratumumab, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 8상태 ACTIVE
AntibodystaleKite, A Gilead CompanyPhase 1

Lenzilumab (Lenzilumab)

Relapsed/Refractory Large B-cell Lymphoma · FRα

#FR#Antibody#Phase1#항체#면역항체+4
효능 ORR 9.9%임상시험 6상태 DISCONTINUED
AntibodystaleRochePhase 2

131I-rituximab (131I-rituximab)

Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 4상태 ACTIVE
AntibodystaleJanssenPhase 1

daratumumab (Darzalex, Actinium Ac 225-DOTA-Daratumumab)

Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia · FRα

#FR#Antibody#Phase1#항체#면역항체+4
임상시험 2상태 RECRUITING
AntibodystaleEli LillyPhase 2

Cetuximab + Irinotecan (Cetuximab + Irinotecan)

Advanced Colorectal Cancer · FRα

#FR#Antibody#Phase2#항체#면역항체+3
효능 ORR 2.081%임상시험 2상태 ACTIVE
AntibodystaleJanssenPhase 1

daratumumab (Darzalex, Indium In 111-DOTA-Daratumumab)

Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia · FRα

#FR#Antibody#Phase1#항체#면역항체+4
임상시험 2상태 RECRUITING
AntibodystaleTakedaPhase 2

Mezagitamab (Mezagitamab)

Relapsed and/or Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 25%임상시험 2상태 ACTIVE
AntibodystaleBeiGenePhase 3

Ociperlimab (Ociperlimab)

Advanced Hepatocellular Carcinoma · FRα

#FR#Antibody#Phase3#항체#면역항체+3
효능 ORR 100%임상시험 2상태 DISCONTINUED

1 / 3 페이지

← 이전다음 →